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Home hemodialysis: a system and
not only a treatment
To the Editor: The paper by Komenda et al.1 deals with a hot
issue in home dialysis: the cost analysis, with particular
attention to the ‘hidden costs’. As home hemodialysis (HHD)
is a context-sensitive treatment, we would like to report on
the situation in Piedmont, northern Italy, which shares with
British Columbia a population of about 4,400,000 inhabitants,
albeit in a smaller, partly mountainous area. In Piedmont,
the cost of dialysis is entirely public; the reimbursement is
per session, according to the care setting (home, satellite,
hospital) and type of treatment (bicarbonate, hemodiaﬁltra-
tion, hemoﬁltration). The home set-up for HHD is reim-
bursed by the Region (1240 Euros, about 1500 USD per
patient), along with a ﬁxed payment for travel, electricity,
telephone, and water expenses (56 Euros, 67 USD per month).
Although our Region has been a pioneer in home and daily
hemodialysis, the patients on HHD have been dramatically
decreasing.2 At the last census in 2009, only 15 of about 3000
dialysis patients were on HHD. A parallel, less severe drop
was observed in peritoneal dialysis.
Three main problems were identiﬁed: reimbursement to
the Centers, rewards to the families, and need for ﬂexibility in
dialysis schedules.
The ‘best prices’ for HHD hardware, supplies, technical
assistance, and water treatment recently obtained from the
dialysis companies range from 75 to 100 Euros per session
(90–120 USD). The reimbursement for HHD (110–125 Euros,
130–150 USD per session, according to the membrane
chosen) is unrewarding for the Centers, as the fee also
includes medical and nursing assistance, the ‘indirect’ costs of
hospital management (indicated in Italy as between 20 and
30%), and the program start-up.
The dialysis population is increasing. Thus, the Regional
Health Council recognized the savings of home treatments
(reduced need for new Centers) and deliberated a monthly
incentive for HHD families (250 Euros, about 300 USD) and a
‘per program’ incentive for peritoneal dialysis.3 This is, to our
knowledge, the ﬁrst European Regional law ﬁnancially
supporting HHD families.
A recent HHD focus group identiﬁed a ﬂexible dialysis
schedule as a requisite.4 Consequently, the design of our
new HHD program included training of ﬂexible duration
(1–6 months), a ﬂexible dialysis schedule (2–7 days per week,
according to the residual glomerular ﬁltration rate and
individual needs), the possibility of integrating home and
in-Center dialysis, and the availability of a second dia-
lysis machine for patients who change residence for over
3 months/year.
The road will be long and hard. We need to lower the costs
of HHD and invest in dedicated facilities. We would like to
thank the authors for raising these fundamental issues and for
demonstrating the feasibility and affordability of a large HHD
program, offering a wide range of schedules. Their experience
may be of help in supporting new HHD programs and
represents an example to be followed in organizing new
facilities.
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The Authors Reply: Piccoli and Salomone1 raise some
insightful comments in their letter entitled ‘Home hemodialysis:
a system and not only a treatment’. Certainly, in terms of
convincing payers and administrators to adequately resource
and promote home hemodialysis as a cost-effective option, our
recent publication in this journal will be of assistance.2 It is
unlikely, however, that costing data alone will be sufﬁcient in
the broad uptake of home hemodialysis therapies.
It has been known for some time that peritoneal dialysis is
much less costly than facility-based hemodialysis.3 Despite
this, there is a dramatic variability of peritoneal dialysis
uptake both within individual health-care systems, with
universal coverage such as Canada, and internationally. Our
group in British Columbia has demonstrated that it is possible
to grow both home hemodialysis and peritoneal dialysis
populations simultaneously with a multifaceted approach to
promote these treatments.4
Piccoli and Salomone endorse some unique incentives for
home therapies, which are likely of considerable value, such as
ﬂexible locations and scheduling and even ﬁnancial incentives
for programs and families. We have found creating a culture
of home-based therapies ﬁrst throughout our renal program
staff and patients is the most effective way of increasing
the penetration of these treatments. No matter what lens
is placed over our promotion effort, quality of life, health
outcomes, or economics, there is an ever-growing body of
evidence to support our approach for improved, more
efﬁcient patient care.
In a global environment of health-care accountability
and responsibility, it will behoove us to work together,
across regional, national, and international boundaries, to
advocate for the best care for patients. Piccoli and Salomone
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remind us that we are working with the same goals, though
in different environments, but that our patient needs
remain constant.
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Cinacalcet and cardiovascular
mortality in hemodialysis patients
To the Editor: I read with interest the observational study of
Block et al.1 suggesting that cinacalcet hydrochloride
signiﬁcantly improves cardiovascular survival in hemodialysis
patients. Inasmuch as the authors note that survival appears
improved with lower serum calcium and phosphorus
levels, the implication of the data cited is that upregulation
of the calcium-sensing receptor may be involved in the
improved outcome.
I bring to your attention work of our group2 in a sheep
burn model and of another group in the spontaneously
hypertensive rat3 in which the calcium receptor has been
identiﬁed in heart endocardial epithelium, microvasculature
of the myocardium, and aortic endothelium and adventitia
by ﬂuorescence deconvolution microscopy2 and in the rat
vascular smooth muscle.3
Although experiments showing a dialysis-associated down-
regulation of the cardiovascular calcium-sensing receptor
have not as yet been reported to my knowledge, the
combination of the observational data reported by Block
et al.1 and the experiments localizing the calcium-sensing
receptor to the cardiovascular system2,3 warrant that the
status of the receptor be documented in a dialysis model as an
important step in understanding the pathophysiology of the
cardiovascular complications of dialysis.
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